Table 1. Patient and treatment characteristics.
| Toxicity and Grade | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anterior | |||||||||||
| Patient | Tumor Site | Histology | T/N/M Classification | Treatment | Dysgeusia | Radiation Dermatitis | Oral Mucositis | Nausea | Vomiting | Weight Loss | Response |
| 1 [66 yo M] | BOT | SCC | T4N3M0 | Induction TPF → CRT (carboplatin) | 2 | 3 | 1 | 0 | 0 | 1 | CR |
| 2 [67 yo M] | BOT | SCC | T2N1M0 | CRT (cetuximab) | 2 | 2 | 1 | 0 | 0 | 0 | CR |
| 3 [58 yo M] | Tonsil | SCC | T2N2bM0 | Induction carbo+pacl →CRT (cisplatin) | 2 | 3 | 0 | 3 | 3 | 2 | CR |
| 4 [38 yo F] | Tonsil | SCC | T2N2bM0 | Ind CT [TPF] → CRT (cisplatin) | 1 | 2 | 0 | 0 | 0 | 0 | CR |
| 5 [59 yo M] | Tonsil | SCC | T3N1M0 | CRT (cisplatin) | 2 | 2 | 1 | 3 | 4 | 3 | CR |
| 6 [61 yo M] | Tonsil | SCC | T2N2bM0 | Induction PCC →CRT (carboplatin) | 2 | 3 | 1 | 2 | 1 | 1 | CR |
| 7 [48 yo M] | Tonsil | SCC | T1N1M0 | RT | 0 | 2 | 0 | 2 | 0 | 1 | CR |
| 8 [63 yo M] | Tonsil | SCC | T2N2bM0 | S →RT | 2 | 3 | 0 | 0 | 0 | 1 | CR |
| 9 [54 yo M] | Unknown | SCC | T0N1M0 | RT | 2 | 3 | 1 | 3 | 0 | 1 | CR |
| 10 [28 yo M] | NPX | SCC | T1N1M0 | Induction TPF →CRT (carboplatin) | 2 | 3 | 0 | 0 | 0 | 1 | CR |
| 11 [33 yo F] | NPX | ACC | T4N0M0 | CRT (cisplatin) | 2 | 0 | 0 | 2 | 1 | 2 | CR |
| 12 [47 yo F] | NPX | ACC | T2N0M0 | CRT (cisplatin) | 2 | 1 | 0 | 2 | 0 | 1 | CR |
| 13 [32 yo F] | NPX | ACC | T4N0M0 | CRT (ciplatin) | 0 | 1 | 0 | 0 | 0 | 0 | PR |
| 14 [37 yo F] | PNS | ACC | Recurrent | S →CRT (cisplatin) | 2 | 2 | 0 | 0 | 0 | 0 | CR |
| 15 [48 yo M] | PNS | ACC | Recurrent | S →CRT (carboplatin) | 2 | 2 | 0 | 3 | 0 | 2 | CR |
Abbreviations: BOT, base of tongue; NPX, nasopharnyx; PNS, paranasal sinus; SCC, squamous cell carcinoma; ACC, adenocarcinoma; CRT, concurrent chemotherapy; TPF, docetaxel, cisplatin, fluorouracil; PCC, paclitaxel, cisplatin, and cyclophosphamide; S, surgery; RT, intensity modulated proton-beam therapy; CR, complete response; PR, partial response.